Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Anouk Deruaz-Luyet"'
Autor:
Steven R. Feldman, MD, Rhonda L. Bohn, ScD, Ran Gao, MS, Stephani Gray, MPH, Sabrina E. Walton, MSPH, Anouk Déruaz-Luyet, PhD, MPH, Jashin J. Wu, MD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 78-83 (2024)
Background: Generalized pustular psoriasis (GPP) is a rare skin disease characterized by episodes of widespread sterile pustules. Methods: A retrospective cohort study using data from the US IBM MarketScan Commercial and Optum Clinformatics Data Mart
Externí odkaz:
https://doaj.org/article/cbdb8723cce74115b9e0c473d1bfc3ca
Autor:
Jashin J. Wu, MD, Ran Gao, MS, Rhonda L. Bohn, ScD, Anouk Déruaz-Luyet, PhD, Stephani Gray, MPH, Frank Baehner, MD, Steven R. Feldman, PhD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 192-194 (2024)
Externí odkaz:
https://doaj.org/article/3e48743cd8bc4fdfa0afc9e574acd253
Autor:
Steven R. Feldman, MD, PhD, Ran Gao, MS, Rhonda L. Bohn, ScD, Stephani Gray, MPH, Sabrina E. Walton, MSPH, Anouk Déruaz-Luyet, PhD, MPH, Jashin J. Wu, MD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 59-61 (2024)
Externí odkaz:
https://doaj.org/article/186d9dc60dab4149bcaeca83157689fe
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reporte
Externí odkaz:
https://doaj.org/article/a409dae7b8d64bffbc67fb3a8cee406b
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/1b45064e466d4e25abc84ea3e931b788
Autor:
Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino, EMPRISE East Asia Study Group
Publikováno v:
Journal of Diabetes Investigation, Vol 14, Iss 3, Pp 417-428 (2023)
Abstract Aims/Introduction The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes an
Externí odkaz:
https://doaj.org/article/4fadce44738c43919f7eaceb3654a8a9
Autor:
Wayne H‐H Sheu, Yutaka Seino, Elise Chia‐Hui Tan, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Wook‐Jin Chung, Koichi Node, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Anastasia Ustyugova, Riho Klement, Anouk Deruaz‐Luyet, Moe H Kyaw, Dae Jung Kim, the EMPRISE East Asia study group
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 5, Pp 810-821 (2022)
ABSTRACT Aims/Introduction We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, versus dipeptidyl peptidase‐4 (DPP‐4) inhib
Externí odkaz:
https://doaj.org/article/7f7c784bc36e45fdb973717cf420b9e6
Autor:
Yutaka Seino, Dae Jung Kim, Daisuke Yabe, Elise Chia‐Hui Tan, Wook‐Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Moe H. Kyaw, Anouk Deruaz‐Luyet, Kimberly G. Brodovicz, Wayne H.‐H. Sheu, the EMPRISE East Asia study group
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 1, Pp n/a-n/a (2021)
Abstract Aim To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study. Materials and methods Data were obtained from the Medical Data Vision d
Externí odkaz:
https://doaj.org/article/b9d082c7bc384035bc5f92b568082777
Autor:
PHYO T. HTOO, HELEN TESFAYE, JULIE M. PAIK, DEBORAH J. WEXLER, MEHDI NAJAFZADEH, ROBERT GLYNN, ANOUK DERUAZ-LUYET, SOULMAZ F. FAZELI FARSANI, LISETTE KOENEMAN, SEBASTIAN SCHNEEWEISS, ELISABETTA PATORNO
Publikováno v:
Diabetes. 71
Within the EMPRISE® monitoring program, we evaluated the cardiovascular effectiveness of empagliflozin (EMPA) vs. glucagon-like peptide-1 receptor agonists (GLP1RA) or liraglutide using data from Medicare and 2 U.S. commercial claims databases [2014
Autor:
PHYO T. HTOO, HELEN TESFAYE, JULIE M. PAIK, DEBORAH J. WEXLER, MEHDI NAJAFZADEH, ROBERT GLYNN, ANOUK DERUAZ-LUYET, SOULMAZ F. FAZELI FARSANI, LISETTE KOENEMAN, SEBASTIAN SCHNEEWEISS, ELISABETTA PATORNO
Publikováno v:
Diabetes. 71
EMPRISE is a 5-year monitoring program that evaluates the effectiveness and safety of empagliflozin (EMPA) using Medicare and 2 U.S. commercial claims [2014-20 (2018 for Medicare) ]. We identified 190,226 patients ≥18 years with type 2 diabetes ini